Cargando…
Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer
Autores principales: | Baar, Joseph, Storkus, Walter J, Finke, James, Butterfield, Lisa, Lazarus, Hillard, Reese, Jane, Downes, Katharine, Budd, Thomas, Brufsky, Adam, Fu, Pingfu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547175/ http://dx.doi.org/10.1186/2051-1426-3-S1-P3 |
Ejemplares similares
-
Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011) -
Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
por: Dillman, Robert O, et al.
Publicado: (2019) -
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma
por: Storkus, Walter J, et al.
Publicado: (2021) -
Monitoring the Initiation and Kinetics of Human Dendritic Cell-Induced Polarization of Autologous Naive CD4(+) T Cells
por: Oth, Tammy, et al.
Publicado: (2014) -
Differential T-Helper Cell Polarization after Allergen-Specific Stimulation of Autologous Dendritic Cells in Polysensitized Allergic Patients
por: Ashjaei, Kazem, et al.
Publicado: (2015)